ClinicalTrials.gg
CompletedNCT01453855Updated Oct 18, 2013Results posted

Travoprost 3-Month Safety and Efficacy Study

A Phase 3 interventional study of Travoprost ophthalmic solution, 0.003% and Travoprost ophthalmic solution, 0.004% in Open-Angle Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-10-18.

Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,099
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.

Enrollment
Largest of 45
1,099 · median 135
Started
2011
with 8 others
Phase 3
16 of 46
none open now
Registered
31st of 46
by date
Lead sponsor
29 of 46
Alcon Research

Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one has the largest enrollment of the 45 interventional ones that give a count, is one of 9 that started in 2011, is one of 16 in phase 3, and was the 31st registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing travoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

The purpose of this study was to demonstrate that the intraocular pressure-lowering efficacy of Travoprost 0.003% is equivalent to TRAVATAN® in adult patients with open-angle glaucoma or ocular hypertension.

Read the detailed description

This study consisted of six visits conducted during two sequential phases. The Screening/Eligibility phase included one screening visit and two eligibility visits. A washout period based on previous ocular medication preceded Eligibility Visit 1. Subjects who met all inclusion/exclusion criteria at both eligibility visits were randomized (1:1) at the second eligibility visit. The Treatment phase consisted of three on-therapy visits (Week 2, Week 6, and Month 3).

03

Conditions studied

  • Open-Angle Glaucoma
  • Ocular Hypertension

Keywords

  • Open-Angle Glaucoma
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of open-angle glaucoma (including open-angle glaucoma with pseudoexfoliation or pigment dispersion) or ocular hypertension.
  • Qualifying intraocular pressure at both eligibility visits.
  • Understand and sign an form.
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Women of if pregnant, breast-feeding, or not on adequate .
  • Severe central visual field loss in either eye.
  • Chronic, recurrent or severe inflammatory eye disease.
  • Best corrected visual acuity (BCVA) score worse than 55 ETDRS letters (equivalent to 20/80 Snellen).
  • Any abnormality preventing reliable applanation tonometry.
  • to prostaglandin analogs or to any component of the study medications.
  • Therapy with another agent within 30 days prior to the Screening Visit.
  • Other protocol-defined exclusion criteria may apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,099 participants (actual)

Study arms

  • Experimental
    Travoprost 0.003%

    Travoprost ophthalmic solution, 0.003%, one drop instilled in each eye, once daily, for three months

    Drug: Travoprost ophthalmic solution, 0.003%

  • Active comparator
    TRAVATAN

    Travoprost ophthalmic solution, 0.004%, one drop instilled in each eye, once daily, for three months

    Drug: Travoprost ophthalmic solution, 0.004%

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Intraocular Pressure (IOP) at Week 2, Week 6, and Month 3 for Each Assessment Time Point (8 AM, 10 AM, and 4 PM)

    As measured by Goldmann applanation tonometry. One eye from each subject was chosen as the study eye and only the study eye was used in the efficacy analysis. A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).

    Time frame: Week 2, Week 6, Month 3 (8 AM, 10 AM, 4 PM)

07

Results

Posted Oct 18, 2013

Participant flow

Subjects were recruited from 60 investigational centers, including 52 in the US, 2 each in Sweden, Germany, and Austria, and 1 each in Spain and Finland.

Participant flow — Overall Study
MilestoneTravoprost 0.003%TRAVATAN
Started442422
Completed432408
Not completed1014
Withdrew: Adverse event34
Withdrew: Lost to follow-up21
Withdrew: Patient decision unrel to adverse event33
Withdrew: Noncompliance10
Withdrew: Inadequate control of iop15
Withdrew: Other01

Outcome measures

PrimaryMean Intraocular Pressure (IOP) at Week 2, Week 6, and Month 3 for Each Assessment Time Point (8 AM, 10 AM, and 4 PM)

As measured by Goldmann applanation tonometry. One eye from each subject was chosen as the study eye and only the study eye was used in the efficacy analysis. A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).

Time frame:
Week 2, Week 6, Month 3 (8 AM, 10 AM, 4 PM)
Reported as:
Least squares mean · millimeters mercury (mmHg)
Mean Intraocular Pressure (IOP) at Week 2, Week 6, and Month 3 for Each Assessment Time Point (8 AM, 10 AM, and 4 PM)
millimeters mercury (mmHg)Travoprost 0.003%TRAVATAN
Week 2 at 8 AM19.4 ± 0.1619.5 ± 0.17
Week 2 at 10 AM18.6 ± 0.1618.6 ± 0.16
Week 2 at 4 PM18.0 ± 0.1618.3 ± 0.16
Week 6 at 8 AM19.3 ± 0.1619.3 ± 0.17
Week 6 at 10 AM18.5 ± 0.1618.6 ± 0.17
Week 6 at 4 PM18.0 ± 0.1618.1 ± 0.17
Month 3 at 8 AM19.2 ± 0.1719.3 ± 0.18
Month 3 at 10 AM18.3 ± 0.1718.6 ± 0.18
Month 3 at 4 PM18.0 ± 0.1618.0 ± 0.17

Adverse events

Collected over Adverse events were collected from time of enrollment to study completion. An adverse event was considered to be any untoward medical occurrence in a patient exposed to the study medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Travoprost 0.003%—5/442 (1.1%)56/442 (12.7%)
TRAVATAN—7/421 (1.7%)64/421 (15.2%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventTravoprost 0.003%TRAVATAN
Chest PainGeneral disorders2/4420/421
CellulitisInfections and infestations0/4421/421
Diabetes mellitusMetabolism and nutrition disorders0/4421/421
Diabetic ketoacidosisMetabolism and nutrition disorders0/4421/421
Drug hypersensitivityImmune system disorders0/4421/421
ErysipelasInfections and infestations0/4421/421
Myocardial infarctionCardiac disorders0/4421/421
NephrolithiasisRenal and urinary disorders0/4421/421
Abdominal painGastrointestinal disorders1/4420/421
Collapse of lungInjury, poisoning and procedural complications1/4420/421
Most frequent other events
Most frequent other events
EventTravoprost 0.003%TRAVATAN
Ocular hyperaemiaEye disorders31/44234/421
Conjunctival hyperaemiaEye disorders25/44230/421

Baseline characteristics

This reporting group includes subjects exposed to the study medication. Note: One subject in the TRAVATAN arm was randomized but discontinued prior to exposure to study medication and is not included in this reporting group.

Age, Customized
Age, Customized(Participants)Travoprost 0.003%TRAVATANTotal
18 to 64 years189193382
≥ 65 years253228481
Sex: Female, Male
Sex: Female, Male(Participants)Travoprost 0.003%TRAVATANTotal
Female269246515
Male173175348
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2011
First posted
Oct 18, 2011
Start
Nov 2011
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Results first posted
Oct 18, 2013
Last update
Oct 18, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01453855
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Oct 18, 2011
Start date
Nov 2011
Primary completion
Aug 2012
Completion
Aug 2012
Results posted
Oct 18, 2013
Last update
Oct 18, 2013

Study contacts

Theresa A Landry, PhD
study director · Alcon Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion